Top 10 Specialty Drug Therapeutic Classes

3. Oncology

The FDA approved 10 oncology therapies in 2015, which helped increase spend 23.7%, while the increase in utilization (9.3%) and unit cost (14.4%) helped drive the trend. The oncology treatment Gleevec and lenalidomide (Revlimid) account for more than 22% of the market share, with Gleevec comprising the largest market share at an increase in unit cost by 19.3%.

2. Multiple sclerosis

MS ranked at number 2 in total trend for medications at 9.7%. The increase found in unit cost (6.2%) and utilization (3.5%) helped drive the total trend. The overall trend was especially influenced by the increase in unit price of the top 5 most prescribed medications, which accounted for 84% of the spend. The unit cost increase for MS drugs was between 3.8% and 9.4%, with glatiramer (Copaxone) being the most widely used and having the highest spend in the class, but a generic version was launched in June 2015. 

1. Inflammatory conditions

When ranked by per member per month (PMPY) spend, inflammatory conditions remained at the top of specialty therapy classes for the seventh consecutive year, trending at 25%. Most of the top drugs within the class are disease modifying anti-rheumatic drugs (DMARDs) responsible for treating psoriasis, rheumatoid arthritis, inflammatory bowel disease, and other conditions as well.
Additionally, the top 2 drugs adalimumab (Humira) and etanercept (Enbrel) saw an increase in unit cost.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Top news of the day across the health care landscape.
The specialty drug market saw a 16% growth rate in 2018.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.